Physician profile
Hunter W Burch
NPI 1306935333
$19,804.75
in general payments reported to CMS, 2019-2025
41 companies · $3,172 in 2025
The $3,172 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,006 · 2020: $1,887 · 2021: $2,438 · 2022: $2,565 · 2023: $3,227 · 2024: $3,510 · 2025: $3,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,610 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,610.37 |
| Education | $298.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,896.43 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Sun Pharmaceutical Industries INC. | $1,622.87 | 2019-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $1,500.17 | 2019-2025 | |
| Janssen Biotech, INC. | $1,338.32 | 2019-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $1,196.99 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $1,115.19 | 2019-2025 | |
| Amgen INC. | $963.38 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $808.42 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Incyte Corporation | $795.76 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $789.27 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $768.59 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $754.64 | 2019-2025 | Nemluvio, Dysport |
| Genzyme Corporation | $723.54 | 2019-2025 | |
| Merz North America, INC. | $632.85 | 2019-2023 | Xeomin |
| Leo Pharma INC. | $631.30 | 2019-2025 | Adbry, Anzupgo, Spevigo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $591.94 | 2022-2025 | Sotyktu |
| Almirall LLC | $541.17 | 2019-2025 | Klisyri, Seysara |
| Arcutis Biotherapeutics, INC. | $387.07 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $342.71 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.91 | 2022-2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $200.45 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $139.78 | 2019-2022 | |
| Allergan, INC. | $127.99 | 2019-2022 | |
| Celgene Corporation | $110.09 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $101.57 | 2019-2023 | Valchlor |
| Organon LLC | $100.61 | 2025 | Vtama |
| Genentech USA, INC. | $72.75 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $49.14 | 2019 | |
| Epi Health, LLC | $44.84 | 2021-2022 | |
| Journey Medical Corporation | $34.17 | 2022 | |
| Verrica Pharmaceuticals INC. | $33.01 | 2024 | Ycanth |
| Biofrontera INC. | $25.24 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Peerless Surgical INC. | $25.00 | 2022 | |
| Fresenius Kabi USA, LLC | $20.78 | 2023 | |
| Encore Dermatology INC. | $18.75 | 2020 | |
| Kerecis Limited | $17.81 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Aclaris Therapeutics, INC. | $16.68 | 2019 | |
| Sensus Healthcare, INC. | $15.81 | 2020 | |
| Organogenesis INC. | $14.01 | 2023 | Puraply |
| Mylan Pharmaceuticals INC. | $12.22 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Burch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.